A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
← catalyst calendarNCT07686120 · readout in 539 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Tigermed Consulting Co., Ltd.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
286estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-30 | estimated | When the study began enrolling |
| Primary completion | 2028-02-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-09 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uncontrolled Hypertension
Interventions
- Drug: baxdrostat 2mg
- Drug: Placebo 2mg
Primary outcome
what the primary-completion date above is the date OFChange from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12
measured Week12
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed